Fenbendazole for humans is a drug that was first used in animals to treat parasitic infestations such as hookworm, whipworm and tapeworm. It was then introduced to scientific studies some years ago for cancer under the brand names Safe-Guard and Panacur. The results of the research revealed that this drug can significantly decrease cancer cell growth and even eradicate some types of cancer in animals. It interferes with cancer cells ability to obtain glucose, which is necessary for their survival and proliferation in laboratory settings and in live subjects. This starving of the cancer cells of their glucose causes them to die in both lab experiments and in patients.
It was also found that this drug can boost the effectiveness of other anti-cancer therapies such as radiation treatment, surgery, berberine and sodium dichloroacetate (DCA). The mechanism by which it enhances these other treatments involves interfering with tubulin polymerization.
In addition, fenbendazole was shown to activate p53 and p21, but not mutant p53. Moreover, the treatment of tumor cells with fenbendazole resulted in G2/M arrest and apoptosis, partly through p53-dependent pathways but also via autophagy and ferroptosis. The cytotoxicity of this drug was enhanced by hypoxia during treatment.
The article concludes that it would be beneficial to study the effect of combining this drug with other anti-cancer therapies in order to enhance their efficacy in the fight against cancer. This includes utilizing this drug along with supplements such as alpha-lipoic acid, coenzyme Q10 and magnesium. fenbendazole for humans